Tesamorelin Is Approved. CJC-1295 Is Living Off Its Reputation.

The same message lands in my inbox three or four times a month, almost word for word: CJC/Ipamorelin is pretty well studied at this point, right? Sometimes there's a forum screenshot attached, and somewhere in the thread a confident guy has written the phrase "the GH peptide studies show."

That phrase is doing an enormous amount of unpaid labor.

Because "the GH peptide studies" isn't a body of evidence. It's a category name stretched over seven or eight compounds that have almost nothing in common evidentially. Tesamorelin is an approved GHRH analogue, approved for a specific clinical indication, used under medical supervision. CJC-1295, with DAC or without, is an unapproved one. Same mechanism family. Same paragraph in every listing description on the internet. Completely different paperwork.

What the new review actually set out to do

There's a newly indexed review pair on performance-enhancing peptides that modulate the GH, IGF-1 axis, and what makes it useful isn't a new finding. It's the organizing principle. The authors built the thing around the gap between what has been published clinically and what people are actually doing with these compounds outside clinical settings. They name CJC-1295, both with and without DAC, as among the unregulated peptides most commonly encountered in clinical practice and in online self-administration protocols.

Read that again. Clinicians are meeting this compound constantly. Not because it was prescribed.

And then the sentence that should reset how you read every product page in this category: the authors state that these peptides lack regulatory approval for physique- or performance-related indications, and that the underlying evidence ranges from regulatory-grade randomized trial data to a complete absence of human studies, leaving the putative performance and body-recomposition benefits uncertain.

Randomized trial data at one end. Zero human studies at the other. Same shelf. Same shopping cart.

The GH Evidence Ladder

So here's the lens I use, and I use it the same way every time. Four rungs.

Rung 1, Regulatory-grade human trials. Randomized human data supporting a specific clinical indication in a specific population. Tesamorelin is the recognizable name here. Two things about that: approval for a defined clinical indication under supervision is not a statement about buying a research vial, and the populations studied in that work are not healthy adults. You cannot slide those results sideways.

Rung 2, Narrow or dated human data. Real humans, but a small study, an old study, or a population that answers a different question than the one you're asking.

Rung 3, Human pharmacology only. It moved GH. That's it. That's the whole finding. Nobody measured fat mass, lean mass, sleep architecture, recovery, injury healing, or anything else you might care about. A GH curve going up is a pharmacology result, not an outcome.

Rung 4, Mechanism and animal work. The receptor logic is sound and something happened in rodents. The review's own range statement tells you the honest ceiling of this rung: for parts of this class, human studies are simply absent.

Now, where does each compound sit? I'll tell you what I can defend and I'll stop there. Tesamorelin is approved; CJC-1295 isn't. Beyond that, I am not going to hand you a tidy chart placing GHRP-2, GHRP-6, hexarelin, ipamorelin and sermorelin on specific rungs, because assigning rungs from memory is exactly the sin the piece is about. The review's authors say the span runs the full distance. Your job is to find out where the specific compound in your cart landed.

Which brings me to my own shelf

We sell a CJC-1295 5mg / Ipamorelin 5mg (No DAC) 10mg blend. It is, by volume, the thing people in this category buy from us most.

It sits on the lower rungs of the ladder I just described. Not rung one. I am not going to describe it using tesamorelin's approval or sermorelin's clinical history, because that credibility isn't mine to spend, and every time a vendor does it the whole category gets a little dumber.

On documentation: that listing has a COA attached, and our certificates name the external laboratory that performed the analysis. It does not print a purity figure on the page, the COA reports one, the page doesn't. That's a gap in how we present it and I'd rather say it than let you assume the page is the document. And a COA tells you what that lab measured on that material. It is not a statement of potency, safety, or fitness for anything.

The review also notes that in unregulated supply chains, product composition, dose and stacking practices are themselves uncertain. I'm in that supply chain. So is everyone selling you this.

The Citation Swap Check

Here's the thing you can actually do, and it takes about ninety seconds.

When someone cites evidence for a GH peptide, name three items: the compound in the study, the population in the study, the endpoint that was measured. If any of the three doesn't match what's in front of you, the evidence is being borrowed, not applied.

Most claims in this category fail on the first item. A good number of the survivors fail on the second, a clinical population is not a healthy adult. And the ones that clear both usually die on the third, because the endpoint was a hormone level and the claim was about your waistline.

One more asymmetry worth sitting with. The benefits are uncertain, per the authors. The reported adverse effects for this class are catalogued in plain language: prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention syndromes, myalgia and arthralgia, injection-site reactions. Uncertain upside, itemized downside. That's not the same thing as "it doesn't work", absent human trials are absent, not negative. But it's a lopsided ledger and pretending otherwise is vendor copy.

If you want to read our paperwork instead of taking my word for it: the CJC-1295 / Ipamorelin listing, COA attached.